Yang Ye-Gui, Li Nuo, Chen Meng-Hua
Department of Intensive Care Medicine, The Second Affiliated Hospital of Guangxi Medical University, Nanning, China.
Guangxi Medical University, Nanning, China.
Ren Fail. 2021 Dec;43(1):606-616. doi: 10.1080/0886022X.2021.1903928.
The present meta-analysis of propensity score-matching studies aimed to compare the long-term survival outcomes and adverse events associated with coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) in patients with chronic kidney disease (CKD).
Electronic databases were searched for studies comparing CABG and PCI in patients with CKD. The search period extended to 13 February 2021. The primary outcome was all-cause mortality, and the secondary endpoints included myocardial infarction, revascularization, and stroke. Odds ratios (ORs) and hazard ratios (HRs) with 95% confidence intervals (CIs) were used to express the pooled effect. Study quality was assessed using the Newcastle-Ottawa scale. The analyses were performed using RevMan 5.3.
Thirteen studies involving 18,005 patients were included in the meta-analysis. Long-term mortality risk was significantly lower in the CABG group than in the PCI group (HR: 0.76, 95% CI: 0.70-0.83, < .001), and similar results were observed in the subgroup analysis of patients undergoing dialysis and for different estimated glomerular filtration rate ranges. The incidence rates of myocardial infarction (OR: 0.25, 95% CI: 0.12-0.54, < .001) and revascularization (OR: 0.17, 95% CI: 0.08-0.35, < .001) were lower in the CABG group than in the PCI group, although there were no significant differences in the incidence of stroke between the two groups (OR: 1.24; 95% CI: 0.89-1.73, > .05). Subgroup analysis among patients on dialysis yielded similar results.
Our propensity score matching analysis revealed that, based on long-term follow-up outcomes, CABG remains superior to PCI in patients with CKD.
本倾向评分匹配研究的荟萃分析旨在比较慢性肾脏病(CKD)患者冠状动脉旁路移植术(CABG)和经皮冠状动脉介入治疗(PCI)的长期生存结局及不良事件。
检索电子数据库中比较CKD患者CABG和PCI的研究。检索期截至2021年2月13日。主要结局为全因死亡率,次要终点包括心肌梗死、血运重建和卒中。采用比值比(OR)和风险比(HR)及95%置信区间(CI)来表示合并效应。使用纽卡斯尔-渥太华量表评估研究质量。采用RevMan 5.3进行分析。
荟萃分析纳入了13项研究,共18,005例患者。CABG组的长期死亡风险显著低于PCI组(HR:0.76,95%CI:0.70 - 0.83,P < 0.001),在接受透析的患者亚组分析以及不同估计肾小球滤过率范围的分析中也观察到了类似结果。CABG组的心肌梗死发生率(OR:0.25,95%CI:0.12 - 0.54,P < 0.001)和血运重建发生率(OR:0.17,95%CI:0.08 - 0.35,P < 0.001)低于PCI组,尽管两组间卒中发生率无显著差异(OR:1.24;95%CI:0.89 - 1.73,P > 0.05)。透析患者亚组分析得出了类似结果。
我们的倾向评分匹配分析表明,基于长期随访结果,CABG在CKD患者中仍优于PCI。